Anti-CD40 Antibody - Pipeline Insight, 2024

Anti-CD40 Antibody - Pipeline Insight, 2024

DelveInsight’s, “Anti-CD40 Antibody - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD40 Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Anti-CD40 Antibody Understanding

Anti-CD40 Antibody: Overview

CD40 is a 48 kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. It is also found on a large portion of melanomas and carcinomas of the lung, breast, colon, prostate, pancreas, kidney, ovary, and head and neck as well as all of B cell malignancies (1–4). The ligand for CD40 (CD154 or CD40L) is expressed on activated T cells and platelets.

Function - The protein receptor encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been found to be essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation.[5] AT-hook transcription factor AKNA is reported to coordinately regulate the expression of this receptor and its ligand, which may be important for homotypic cell interactions.

Anti-CD40 Antibody - CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells. Agonistic CD40 antibodies have been shown to substitute for T cell help provided by CD4+ lymphocytes in murine models of T cell-mediated immunity.

Anti-CD40 Antibody Emerging Drugs Chapters

This segment of the Anti-CD40 Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anti-CD40 Antibody Emerging Drugs

• ABBV-927: AbbVie

ABBV-927 is an agonistic anti-CD40 monoclonal antibody that is being investigated in a Phase 1 clinical trial for solid tumors and in phase I/II for pancreatic cancer.

• GEN1042: Mirati Therapeutics

DuoBody®-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent T-cell activation, using an inert DuoBody® format.

• Sotigalimab: Apexigen

Sotigalimab is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. Sotigalimab targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of Sotigalimab to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. Sotigalimab is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.

Further product details are provided in the report……..

Anti-CD40 Antibody: Therapeutic Assessment

This segment of the report provides insights about the different Anti-CD40 Antibody drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Anti-CD40 Antibody

There are approx. 10+ key companies which are developing the Anti-CD40 Antibody. The companies which have their Anti-CD40 Antibody drug candidates in the most advanced stage, i.e. phase II include, Apexigen.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Anti-CD40 Antibody pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anti-CD40 Antibody: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD40 Antibody therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD40 Antibody drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD40 Antibody R&D. The therapies under development are focused on novel approaches for Anti-CD40 Antibody.

Anti-CD40 Antibody Report Insights

• Anti-CD40 Antibody Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Anti-CD40 Antibody Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Anti-CD40 Antibody drugs?
• How many Anti-CD40 Antibody drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD40 Antibody?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD40 Antibody therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anti-CD40 Antibody and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AbbVie
• Genmab
• Apexigen
• Kiniksa Pharmaceuticals
• Eledon Pharmaceuticals
• Seagen
• Celldex
• Eucure Biopharma
• Glycotope
• Biogen
• Astellas Pharma
• Kyowa Kirin
• Boston Immune Technologies and Therapeutics
• Bristol-Myers Squibb

Key Products

• ABBV-927
• GEN 1042
• Sotigalimab
• KPL 404
• AT-1501
• SEA-CD40
• CDX-1140
• YH003
• CD40-GEX
• Dapirolizumab pegol
• Bleselumab
• BITD 401412
• BMS 986325